Asset Management One Co. Ltd. Purchases 39,464 Shares of Pfizer Inc. (NYSE:PFE)

Asset Management One Co. Ltd. lifted its position in Pfizer Inc. (NYSE:PFE) by 1.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,278,669 shares of the biopharmaceutical company’s stock after purchasing an additional 39,464 shares during the quarter. Asset Management One Co. Ltd.’s holdings in Pfizer were worth $65,945,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Olistico Wealth LLC bought a new position in Pfizer in the second quarter valued at $25,000. MFA Wealth Advisors LLC purchased a new stake in Pfizer during the second quarter valued at about $29,000. Quarry LP purchased a new stake in Pfizer during the second quarter valued at about $31,000. Financial Connections Group Inc. purchased a new stake in shares of Pfizer during the second quarter worth about $34,000. Finally, ESL Trust Services LLC purchased a new stake in shares of Pfizer during the first quarter worth about $37,000. Institutional investors own 68.36% of the company’s stock.

Insider Transactions at Pfizer

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of Pfizer stock in a transaction dated Wednesday, October 30th. The shares were purchased at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the acquisition, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. This represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Insiders own 0.06% of the company’s stock.

Pfizer Price Performance

Shares of PFE traded down $0.24 during trading hours on Monday, reaching $27.85. 5,140,455 shares of the stock traded hands, compared to its average volume of 37,113,066. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $31.54. The company’s 50-day moving average price is $29.03 and its two-hundred day moving average price is $28.62. The company has a market cap of $157.82 billion, a P/E ratio of 37.96, a price-to-earnings-growth ratio of 0.90 and a beta of 0.67.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. The company had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.40%. Pfizer’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.17) EPS. On average, analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be issued a $0.42 dividend. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.03%. Pfizer’s dividend payout ratio (DPR) is presently 227.03%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Barclays increased their price target on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Citigroup started coverage on shares of Pfizer in a research note on Friday, October 25th. They set a “neutral” rating and a $30.00 target price for the company. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and raised their target price for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. UBS Group raised their target price on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Finally, Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Eight investment analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $33.58.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.